Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses.
Sellner J, Cepok S, Kalluri SR, Nestler A, Kleiter I, Kümpfel T, Linker R, Melms A, Menge T, Tumani H, Paul F, Hemmer B, Berthele A. Sellner J, et al. Among authors: kumpfel t. Neurochem Int. 2010 Nov;57(6):662-7. doi: 10.1016/j.neuint.2010.08.003. Epub 2010 Aug 10. Neurochem Int. 2010. PMID: 20705110
Failure of natalizumab to prevent relapses in neuromyelitis optica.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Kleiter I, et al. Among authors: kumpfel t. Arch Neurol. 2012 Feb;69(2):239-45. doi: 10.1001/archneurol.2011.216. Arch Neurol. 2012. PMID: 22332191
Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply.
Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Kleiter I, et al. Among authors: kumpfel t. Arch Neurol. 2012 Aug 1;69(8):1085-6. doi: 10.1001/archneurol.2012.1316. Arch Neurol. 2012. PMID: 23753805 No abstract available.
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfár A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Goelz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, Wiendl H. Schwab N, et al. Among authors: kumpfel t. Neurology. 2013 Sep 3;81(10):865-71. doi: 10.1212/WNL.0b013e3182a351fb. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925765
253 results